LONDON (AFX) - Amgen Inc said interim data from two Phase 2 clinical studies showed that treatment with denosumab resulted in a rapid suppression of bone turnover among advanced cancer patients with bone metastases.
Bone metastases are one of the most frequent causes of pain in people with cancer and may lead to fractures or the need for bone surgery or radiation.
'Our data show denosumab was clinically active as it reduced levels of a bone turnover biomarker in both IV bisphosphonate-naive and -treated patients,' said Allan Lipton MD, professor of Medicine/Oncology at Penn State University, Milton S. Hershey College of Medicine in Hershey, PA.
Amgen's denosumab is an investigational RANK Ligand inhibitor being studied for its potential to prevent and treat bone destruction. newsdesk@afxnews.com vs COPYRIGHT Copyright AFX News Limited 2005. All rights reserved. The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News. AFX News and AFX Financial News Logo are registered trademarks of AFX News Limited